We can’t show the full text here under this license. Use the link below to read it at the source.
Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
Delaying stronger treatment with a hormone-based drug in type 2 diabetes patients not controlled by basic insulin
AI simplified
Abstract
A total of 139 patients initiated early intensification with a GLP-1 receptor agonist () for type 2 diabetes (T2D).
- Delayed intensification with a GLP-1 RA resulted in a smaller reduction in levels (-0.68%) compared to early intensification (-1.01%).
- The rate of overall hypoglycaemia was numerically higher in the delayed intensification group (0.26 events/patient-years) than in the early group (0.06 events/patient-years).
- Total healthcare costs increased by $5266 in the no intensification group, reduced by $560 in the early intensification group, and increased by $1943 in the delayed group.
AI simplified
Key numbers
-0.68%
Reduction
Change in from baseline in the delayed group.
0.26 events/patient-years
Overall Hypoglycaemia Rate
Rate of hypoglycaemic events in the delayed intensification group.
+5266 USD
Healthcare Cost Change
Increase in semi-annual healthcare costs in the no intensification group.